Researchers looked through medical studies from late 2024 to help doctors create new guidelines for treating high cholesterol in 2026.

What we've found so far is that the evidence we've reviewed supports the idea that a literature search was conducted on human studies from October to December 2024 to help develop the 2026 dyslipidemia guideline. Our analysis of the available information shows that researchers reviewed medical studies from late 2024 as part of the process to assist doctors in creating updated guidance for managing high cholesterol [1]. The single assertion we analyzed indicates that this literature search was carried out specifically to inform the development of the 2026 guidelines. It describes the effort as part of the groundwork for shaping clinical recommendations, focusing on human research published during that three-month window [1]. We did not find any claims that contradict this. At this point, our analysis is based on a limited number of assertions—just one—but what we’ve reviewed leans toward the conclusion that a targeted review of late 2024 studies was indeed part of the guideline development process. We cannot say how extensive the search was, which databases were used, or how many individual studies were included, as that detail is not in the evidence we have. As we continue to analyze new information, our understanding may evolve. For now, the available evidence suggests that recent human studies were considered early in the process of updating cholesterol treatment guidance. Practical takeaway: If you're following updates on cholesterol care, it appears recent research from late 2024 was included in early planning for new guidelines—though the full picture may become clearer as more data emerges.